MDT · 10-Q · 2026Q3 · Full report

Diabetes Business Separation

Medtronic plc · 2026-09-03 · Importance 44 · Surprise 60 · In source text

Medtronic announced in May 2025 that it intended to separate its Diabetes Business into a new independent publicly traded company, MiniMed Group, Inc. MiniMed completed an initial public offering on March 9, 2026, but Medtronic retained a controlling financial interest, so its condensed consolidated financial statements continue to include MiniMed’s financial results. Medtronic plans to complete the Diabetes Business separation during fiscal year 2027 and expects separation activities, transition arrangements, infrastructure changes, and related costs to affect future results and financial condition.

Key facts

• Medtronic plans to complete the separation of its Diabetes Business within this fiscal year (fiscal year 2027). source
• On May 2025 the Company announced its intent to separate the Diabetes Business to create MiniMed Group, Inc., and MiniMed completed an initial public offering on March 9, 2026 while Medtronic retained a controlling financial interest. source
• The Company noted planned exit of certain businesses, including the Diabetes Business, may involve separation activities, costs, and risks that could affect future results and financial condition. source
• Diabetes net sales for the three months ended July 31, 2026 were $843 million, an increase of 17% compared to the corresponding period in the prior fiscal year. source

Impact estimates